Discover SLU-PP-332 dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
SLU-PP-332 is a pan-agonist of the estrogen-related receptor (ERR) family — alpha, beta, and gamma — engineered as an "exercise mimetic" with preclinical rodent work showing improved running endurance, mitochondrial biogenesis, and fat loss without exercise. This data captures the dose amounts, vial sizes, and diluent volumes researchers most commonly select when working with SLU-PP-332.
SLU-PP-332 is a small-molecule pan-agonist of the estrogen-related receptor (ERR) family — ERR-alpha, ERR-beta, and ERR-gamma — developed at Saint Louis University in the laboratory of Thomas Burris as part of a broader nuclear-receptor pharmacology program. The estrogen-related receptors are orphan nuclear receptors structurally related to the classical estrogen receptors but with no known endogenous ligand; they are master regulators of mitochondrial biogenesis, oxidative metabolism, and Type I (slow-twitch oxidative) muscle fiber programming, and ERR signaling is one of the canonical pathways activated by physical exercise. SLU-PP-332 is the most fully characterized synthetic ERR pan-agonist published to date — the molecule is conceptually positioned as an "exercise mimetic" that engages the same downstream transcriptional programs as endurance training without the training itself.
SLU-PP-332 is a small-molecule pan-agonist of the estrogen-related receptors (ERRα/β/γ), most often sourced for metabolic and "exercise-mimetic" research after 2023 mouse studies. It is not a peptide and not a SARM. No clinical trial has been run and no human safety data exist; it ships as a research powder, typically dissolved for injection in published animal work.
The estrogen-related receptors (ERRα, ERRβ, ERRγ) are orphan nuclear receptors — they do not bind estrogen despite the name — that act as master transcriptional regulators of mitochondrial-biogenesis, fatty-acid-oxidation, and oxidative-phosphorylation gene programs. SLU-PP-332 is a pan-ERR agonist that drives transcriptional upregulation of these mitochondrial and energy-metabolism programs across skeletal muscle, brown adipose tissue, and liver, producing the exercise-mimetic metabolic phenotype in mice. The molecule is administered by intraperitoneal injection in published in-vivo work.
Billon et al. (J Med Chem 2023) characterised SLU-PP-332 as a pan-ERR agonist with metabolic and exercise-mimetic effects in mice. Earlier Burris-lab work characterised the SLU-PP series chemistry and ERR pharmacology in detail. Follow-on academic work has explored SLU-PP-332 in models of heart failure, obesity, and skeletal-muscle adaptation, with the molecule continuing to be used primarily as a pharmacological tool rather than as a clinical candidate. gov trial of SLU-PP-332 in any indication; consumer use sits entirely outside any clinical framework or human-safety evidence base.
SLU-PP-332 has a reported half-life of ~2 hours (pre-clinical estimate), and the dose intervals researchers model most often fall around once or twice daily. This ERR agonist has a short half-life in animal studies and clears quickly between doses. No human pharmacokinetic data exist. It is catalogued under Weight Loss on WPA.
96 SLU-PP-332 reconstitution calculations have been logged by the WPA community. The most common dose entered is 1mg (22 calculations). The median dose across all sessions is 625mcg. The most common bacteriostatic water volume is 2mL. The most popular vial size is 5mg (82 sessions). The most common dosing frequency is daily (7x/week) (12 logged protocols), followed by 5x/week (3).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.